![logo](/logos/ACW.AX.webp)
Actinogen Medical Limited
ASX:ACW.AX
0.04 (AUD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Actinogen Medical Limited |
Symbool | ACW.AX |
Munteenheid | AUD |
Prijs | 0.039 |
Beurswaarde | 93,168,965 |
Dividendpercentage | 0% |
52-weken bereik | 0.015 - 0.099 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. |
Website | https://www.actinogen.com.au |
An error occurred while fetching data.
Over Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)